Phase 1 Study of Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-IV Non-Small Cell Lung Cancer and Poor Performance Status
- To escalate the dose of accelerated hypofractionated image-guided conformal
radiotherapy to a potent tumoricidal dose without exceeding the maximum-tolerated dose
in patients with recurrent or stage II-IV non-small cell lung cancer and poor
- To evaluate local regional tumor control and overall survival of patients treated with
OUTLINE: Patients undergo accelerated hypofractionated image-guided conformal radiotherapy
once daily, 5 days a week, for 3 weeks (15 fractions). Treatment continues in the absence of
disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up periodically for up to 5 years.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Robert D. Timmerman, MD
Simmons Cancer Center
United States: Food and Drug Administration
|Stanford University||Stanford, California 94305|
|University of Texas Southwestern Medical Center||Dallas, Texas|